News

Table of Contents:

0:00 Opening

0:44 Introduction to Healios’ ARDS Program / Hardy TS Kagimoto, MD. CEO, Healios K.K.

4:00 ARDS, the current standard of care, and the unmet medical need. / Lorraine B. Ware, MD. Vanderbilt University.

19:03 The promise of cell therapy in ARDS. / Michael A. Matthay, MD. University of California San Francisco.

29:37 Q&A

32:07 The science and data in support of invimestrocel in ARDS. / Sarah Busch, PhD. Chief Scientific Officer, Healios NA, Inc.

40:30 REVIVE-ARDS, a global Phase 3 study to confirm the efficacy of invimestrocel in pneumonia-induced ARDS. / Eric Jenkins, MD. Medical Consultant, Healios NA, Inc.

56:14 An ARDS patient experience and the need for a new therapy. / Eileen Rubin. President & CEO, ARDS Foundation.

1:11:30 A soldier’s experience and the need for new therapies to serve the United States military. / DJ Skelton, Advisor, Healios K.K.

1:23:44 Q&A

1:42:27 Closing Remarks / Richard Kincaid, CFO, Healios K.K.